期刊文献+

急性冠状动脉综合征介入治疗围手术期IL-6、IL-8及CRP的变化 被引量:3

下载PDF
导出
摘要 目的观察急性冠状动脉综合征(ACS)患者介入治疗围术期白细胞介素6(IL-6)、白细胞介素8(IL-8)及高敏C反应蛋白(hs-CRP)的变化情况及与疾病的相关性。方法收集122例患者介入治疗术前、术后血液样本,采用ELISA检测患者血清中的IL-6和IL-8表达水平,免疫散射比浊法检测样本中hs-CRP表达水平,并运用描述性统计、秩和检验、相关性分析等方法进行统计学分析。结果介入治疗患者手术前后IL-8和hs-CRP水平差异有显著性(P<0.05)。术前hs-CRP水平在急性心肌梗死(AMI)患者水平均较不稳定型心绞痛(UAP)患者水平高(P<0.05),且冠状动脉双支病变患者较单支病变的患者高(P<0.05)。术后3个指标在AMI及UAP患者间均无统计学意义(P<0.05)。结论 hs-CRP可能是导致ACS的危险因素,可能与ACS的发生发展有关。hs-CRP和IL-8可用于ACS介入治疗围手术期患者的病情观察。
出处 《广东医学》 CAS CSCD 北大核心 2010年第15期1969-1970,共2页 Guangdong Medical Journal
基金 国家十一五科技支撑重大项目资助(编号:2006BAI04A01)
  • 相关文献

参考文献11

  • 1GRONHOLDT M L,DALAGER PEDERSEN S,FALK E.Coronary atherosclerosis:determinants of plaque rupture[J].Eur Heart J,1998,19(Suppl C):C24-C29.
  • 2MULVIHILL N T,FOLEY J B.Inflammation in acute coronary syndromes[J].Heart,2002,87(3):201-204.
  • 3ROSS R.Atherosclerosis-an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
  • 4BRAUNWALD E,ANTMAN E M,BEASLEY J W,et al.ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction:executive summary and recommendations.A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina)[J].Circulation,2000,102(10):1193-1209.
  • 5INOUE T,KATO T,UCHIDA T,et al.Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting[J].J Am Coll Cardiol,2005,46(2):239-245.
  • 6卢强.冠状动脉支架植入术后早期炎性标记物的观察[J].河北医药,2009,31(20):2738-2739. 被引量:5
  • 7郭士金.急性冠状动脉综合征患者血清可溶性细胞间粘附分子-1与超敏C-反应蛋白的测定及其临床意义[J].实用医技杂志,2007,14(20):2754-2755. 被引量:1
  • 8李涛涛,陈小平.急性冠脉综合征患者高敏C-反应蛋白水平及阿托伐他汀的干预作用[J].中西医结合心脑血管病杂志,2010,8(1):30-31. 被引量:11
  • 9IKEDA U,ITO T,SHIMADA K.Interleukin-6 and acute coronary syndrome[J].Clin Cardiol,2001,24(11):701-704.
  • 10MIYAO Y,YASUE H,OGAWA H,et al.Elevated plasma interleukin-6 levels in patients with acute myocardial infarction[J].Am Heart J,1993,126(6):1299-1304.

二级参考文献15

  • 1Walter DH, Fichtlscherer S, Sellwig M, et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol,2001,37 :839-846.
  • 2Farb A, Weber DK, Kolodgie KD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation, 2002, 105: 2974 -2980.
  • 3Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary artery stenting in patients with stable angina. Am J Cardiol, 1998,82:515-518.
  • 4Aggarwal A, Schneider D J, Terrien EF, et al. Comparison of effects of abciximab versus eptifabide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardio1,2003,91 : 1346-1349.
  • 5Ridker PM, Rifai N, Pfeffer MA, et al. Long term effects of pravastatin on plasma concentration of C-reactive protein. Circulation, 1999, 100: 230-235.
  • 6Patti G, Di Sciascio G, D' Ambrosio A, et al. Prognostic value of interleu- kin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol,2002 ,89 :372-376.
  • 7Heeschen C, Dimmeler S, Hamm CW, et al. CAPTURE Study Investigatiors. Soluble CIM0 ligand in acute coronary syndromes. New Engl J Med ,2003,348 : 1104-1111.
  • 8Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation, 1998,98:2370-2376.
  • 9LeMay LG, Otterness IG, Vander AJ, et al. In vivo evidence that the rise in plasma IL-6 following injection of a fever-reducing dose of LPS is mediated by IL-1beta. Cytokine, 1990,2 : 199-204.
  • 10Libby P, Ridker PM, Maseri A. Inflammation and atherosis[J]. Circulation, 2002,105 ( 1 ): 1135 - 1143.

共引文献14

同被引文献28

  • 1HARTFORDM,WIKLUND O,MATTSSON HULEN L,et al.C-reactive protein,Interleukin-6,secretory phospholipase A2 groupⅡA and inter-cdl2 lular adhesion molecule-1 in the prediction of late outcome event after acute coronary syndromes[J].J Intern Med,2007,262(5):526-536.
  • 2DE LEMOS J A,MORROW D A,BLAZING M A,et al.Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes:results from the A to Z trial[J].J Am Coll Cardiol,2007,50(22):2117-2124.
  • 3PASCERI V,CHENG J S,WILLERSON J T,et al.Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs[J].Circulation,2001,103(21):2531-2534.
  • 4BURKE A P,TRACY R P,KOLODGIE F,et al.Elevated C-reactive protein values and atherosclersis in sudden coronarydeath:association with different pathologies[J].Circulation,2002,105(17):2019-2023.
  • 5HONG M K,LEE C W,KIM Y H,et al.Independent predictors of multiple vulnerable plaque in 143 patients with acute coronary syndrome:a prospective study of three-vssel intravascular ultrasound[J].J Am Coll Cardiol,2004,43(5):A73.
  • 6WERLE M,SCLMAL U.Hanna K1MCP-l induces activation of MAP kinases ERK,JNKand p38 MAPK in human endothelial cells[J].Cardiovasc Res,2002,56(2):284-292.
  • 7DE LEMOS J A,MORROW D A,SABATINE M S,et al.Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes[J].Circulation,2003,107(5):690-695.
  • 8康维强,宋达琳,郭新贵,李梅,滕金龙,任国瑞.急性冠状动脉综合征患者血管因子与冠状动脉斑块特征的相关性研究[J].中华心血管病杂志,2007,35(11):1020-1023. 被引量:21
  • 9Yamamoto Y, Otani H, lwasaka J, et aL Comparison of neointimal morphology of in-stent restenosis with siroli mus-eluting stents versus bare metal stents:virtua] histol-ogy-intravascular ultrasound analysis [J]. Cardiovasc In- terv Ther,2011,26(3) : 186-192.
  • 10Cekici Y, Korkmaz H ,Celik A, et al. The effect of the du- ration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome [J]. Clin Invest Med,2011,34(4) E211.

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部